SAB05 / Santa Ana Bio - LARVOL DELTA

Santa Ana Bio to Present Preclinical Data on SAB05, a CD40-Targeted Glucocorticoid Antibody-Drug Conjugate, at ACR Convergence 2026 (GlobeNewswire) - "SAB05 delivers a highly potent glucocorticoid to CD40-expressing cells that drive autoimmune and inflammatory disease."

Preclinical • Immunology • Inflammation

SAB05, a CD40-Targeted Antibody-Drug Conjugate of a Highly Potent Glucocorticoid, Delivers Cell-Selective Immunosuppression and Disease Control with Steroid-Sparing Safety in Models of Autoimmune and Inflammatory Disease (ACR Convergence 2026) - "SAB05 is an Fc-null, CD40-targeted antibody-drug conjugate (ADC; drug-to-antibody ratio 4) that blocks CD40-CD40L signaling and delivers a low-permeability GC with a potency ~130-fold above dexamethasone. By restricting GR activation to CD40+ cells, SAB05 achieves complete suppression of inflammatory responses in vitro and near-complete disease modification at Q14D dosing in therapeutic CIA with body weight gain rather than the loss seen with free GC payload. This uncoupling of efficacy from systemic GC toxicity supports development of SAB05 to deliver glucocorticoid-level efficacy without systemic steroid toxicity in patients with immune mediated diseases."

ADC • Clinical • IO biomarker • Immunology • Inflammation • CD40 • CD40LG • FKBP5 • IL4 • IL6